Systematic Review
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2020; 8(4): 771-781
Published online Feb 26, 2020. doi: 10.12998/wjcc.v8.i4.771
Lymphoepithelioma-like carcinoma of the upper urinary tract: A systematic review of case reports
Shi-Cong Lai, Samuel Seery, Wei Zhang, Ming Liu, Guan Zhang, Jian-Ye Wang
Shi-Cong Lai, Ming Liu, Jian-Ye Wang, Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
Shi-Cong Lai, Ming Liu, Jian-Ye Wang, Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
Samuel Seery, School of Humanities and Social Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Wei Zhang, Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
Guan Zhang, Department of Urology, China-Japan Friendship Hospital, Beijing 100029, China
Author contributions: Lai SC and Seery S designed the study, conducted the systematic literature search to identify all pertinent studies, assessed eligibility and quality of each selected study, as well as performed data extraction and statistical analysis; Zhang W and Liu M coordinated the study and performed data acquisition; Lai SC, Seery S and Zhang G participated in collecting and interpreting the data, drafted and revised the paper; Zhang G and Wang JY participated in critical reviewing the paper; All authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jian-Ye Wang, MD, Professor, Surgeon, Surgical Oncologist, Department of Urology, Beijing Hospital, National Center of Gerontology, No. 1 Dahua Road, Dong Dan, Beijing 100730, China. wangjy@bjhmoh.cn
Received: October 20, 2019
Peer-review started: October 20, 2019
First decision: December 4, 2019
Revised: December 11, 2019
Accepted: December 22, 2019
Article in press: December 22, 2019
Published online: February 26, 2020
Abstract
BACKGROUND

Lymphoepithelioma-like carcinomas (LELCs) are rare, malignant epithelial tumors, generally considered a subtype of squamous cell carcinoma. LELCs are undifferentiated and can occur in multiple tissues, although LELCs in the urinary tract are extremely rare. As such, evidence does not provide clinicians with guidelines for the best practices. Even though this is a rare disease, it is associated with high morbidity and mortality. Therefore, we must learn to differentiate LELC types and identify risk factors for early identification.

AIM

To develop an evidence base to guide clinicians treating primary LELCs of the upper urinary tract (UUT-LELC).

METHODS

We performed a systematic review of all reports on UUT-LELC from the first published case in 1998 until October 2019, according to the PRISMA. A database was then developed by extracting data from previously published reports in order to analyze interactions between clinical characteristics, pathological features, interventions and outcomes. Survival was analyzed using Kaplan–Meier estimates, which were compared using log rank tests.

RESULTS

A total of 28 previously published cases were identified for inclusion. The median age was 72 years with a male to female ratio of 4:3. Pure type LELCs were most common with 48.3% (n = 14), followed by 37.9% (n = 11) predominant LELCs and 3.4% (n = 1) focal LELCs. Epstein-Barr virus testing was negative in all cases. Fourteen patients received radical nephroureterectomy (RNU)-based intervention. Twenty-three patients survived with no evidence of further metastasis, although six died before the median 18 mo follow-up point. Survival analysis suggests pure histological subtypes, and patients who receive complete tumor resection have more favorable prognoses. As always in cancer care, early identification generally increases the probability of interventional success.

CONCLUSION

The most effective treatment for UUT-LELC is RNU-based therapy. Since cases are few in number, case reporting must be enhanced and publishing encouraged to both save and prolong lives.

Keywords: Lymphoepithelioma-like carcinoma, Prognosis, Radical nephroureterectomy, Upper urinary tract, Systematic review, Case report

Core tip: Lymphoepithelioma-like carcinomas in the urinary tract are extremely rare, hence there is little evidence to provide clinical guidelines. Of the 28 participants included in this systematic review of case reports, 23 patients survived with no evidence of further metastasis. Survival analysis suggests pure histological subtypes, and patients who receive complete tumor resection have more favorable prognoses. As always in cancer care, early identification generally increases the probability of interventional success, although this evidence base must be developed with more rigorous testing and case reporting.